Age-related macular degeneration: a target for nanotechnology derived medicines
Authors:
Open Access
- 1 March 2007
- journal article
- review article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 2 (1) , 65-77
Abstract
Despite the fact that the retina is a fairly accessible portion of the central nervous system, there are virtually no treatments for early age-related macular degeneration (AMD). AMD is a degenerative retinal disease that causes progressive loss of central vision and is the leading cause of irreversible vision loss and legal blindness in individuals over the age of 50. Both environmental and genetic components play a role in its development. AMD is a multifactorial disease with characteristics that include drusen, hyperpigmentation and/or hypopigmentation of the retinal pigment epithelium (RPE), geographic atrophy and, in a subset of patients, late-stage choroidal neovascularization (CNV). Drugs that inhibit vascular endothelial growth factor (VEGF) have proven effective in treating late-stage CNV, but optimal means of drug delivery remains to be determined. Microscopic particles, whose size is on the nanometer scale, show considerable promise for drug delivery to the retina, for gene therapy, and for powering prosthetic "artificial retinas." This article summarizes the pathophysiology of AMD stressing potential applications from nanotechnology.Keywords
This publication has 103 references indexed in Scilit:
- Year 2 Efficacy Results of 2 Randomized Controlled Clinical Trials of Pegaptanib for Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- H244R VSX1 Is Associated with Selective Cone ON Bipolar Cell Dysfunction and Macular Degeneration in a PPCD FamilyInvestigative Ophthalmology & Visual Science, 2006
- Complement Factor H Polymorphism in Age-Related Macular DegenerationScience, 2005
- Construction and Delivery of Tissue-Engineered Human Retinal Pigment Epithelial Cell Sheets, Using Magnetite Nanoparticles and Magnetic ForceTissue Engineering, 2005
- Antioxidant vitamin and mineral supplements for age-related macular degeneration2002
- Genetic influence on early age-related maculopathyOphthalmology, 2002
- Vision outcome at age 2 years in a low birth weight populationPediatric Neurology, 1996
- Lipofuscin of the retinal pigment epithelium: A reviewEye, 1995
- Effect of Elastin Peptides on Vascular ToneJournal of Vascular Research, 1995
- Evolution of soft drusen in age-related macular degenerationEye, 1994